Redhill Biopharma Ltd (RDHL) Stock Analysis

Redhill Biopharma Ltd (RDHL) is a publicly traded company in the HEALTHCARE sector. It trades at $1.01, carries a market capitalization of $5.19M. This page summarizes the public market data, fundamentals, and frequently asked questions for RDHL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Redhill Biopharma Ltd currently has a Bullish sentiment score of 0.31.

About Redhill Biopharma Ltd

RedHill Biopharma Ltd. (RDHL) is a Tel Aviv-based specialty biopharmaceutical company focused on developing and commercializing innovative therapeutic solutions primarily for gastrointestinal and infectious diseases. The company boasts a promising pipeline that features proprietary products alongside strategic partnerships, aimed at addressing substantial unmet medical needs. Leveraging its advanced clinical research capabilities and regulatory expertise, RedHill is strategically positioned t...

GNG Research Analysis

GNG Research scores Redhill Biopharma Ltd (RDHL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RDHL.

Frequently Asked Questions

Does RDHL pay dividends?

Redhill Biopharma Ltd (RDHL) does not currently pay a regular dividend.

What is RDHL's market cap?

Redhill Biopharma Ltd (RDHL) has a market capitalization of $5.19M with a current stock price of $1.01.